Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pathology

Understanding Your Diagnosis: Erdheim-Chester Disease (ECD)

At a Glance

Erdheim-Chester disease is a rare multisystem disorder in which abnormal immune cells called histiocytes build up in tissues and cause inflammation. Acquired mutations such as BRAF V600E can support diagnosis and guide care, but a negative test does not rule out the disease.

Hearing that you have Erdheim-Chester Disease (ECD) often brings a mix of relief and confusion. Relief comes because you finally have a name for symptoms that may have puzzled doctors for years, and confusion arises because ECD is a disease that even many medical professionals have never encountered [1][2].

What is Erdheim-Chester Disease?

At its core, ECD is a rare type of clonal disorder known as a histiocytic neoplasm [3][4]. In the past, doctors often viewed it as an inflammatory or storage disorder, but modern research has redefined it as a “clonal” disease—meaning it is driven by an acquired genetic change in specific lesional histiocytes or related myeloid-lineage cells [5].

The disease involves the accumulation of histiocytes, which are a type of white blood cell that normally helps your immune system fight infections and clear away debris [6]. In ECD, these cells don’t behave normally. Instead, they accumulate inappropriately and infiltrate different parts of the body, where they settle and cause trouble [7].

How the Disease Behaves

ECD is often described as a “multisystem” disease because these abnormal histiocytes can infiltrate almost anywhere [8]. When they gather in a specific organ or tissue, they do two things:

  1. Physical Infiltration: The cells pile up and form “infiltrates,” which can look like masses or thickening of the tissue on imaging scans [9].
  2. Chemical Signal Overload: These abnormal cells pump out high levels of cytokines, which are chemical signals that cause intense inflammation [10]. This inflammation can damage surrounding healthy tissue even if the histiocytes aren’t directly touching it.

The way ECD affects you depends entirely on where these cells have decided to settle. While it commonly affects the long bones of the legs, it can also involve the heart, lungs, brain, or the area behind the kidneys [11][12].

The Role of Genetic “Drivers”

Researchers have discovered that in the majority of patients, the engine driving this cell accumulation is a specific genetic mutation [13]. The most common one is called BRAF V600E, found in about half to two-thirds of cases [14][15]. Other mutations in the MAPK pathway (a signaling chain that tells cells when to grow) can also be responsible [16]. These mutations are “somatic,” meaning they are acquired mutations that occurred in a disease-cell clone at some point during your life. They are generally not inherited or passed to your children [11]. It is also important to note that a negative test does not completely rule out ECD, as not every patient will have an identifiable mutation.

Understanding the Rarity

ECD is exceptionally rare. Because it is so rare, there is no “typical” patient, though it is most frequently diagnosed in adults in their 50s or 60s [17][18].

Feature Common Observation
Typical Age at Diagnosis Most frequently identified in adults in their 50s or 60s [17][18]
Sex Distribution Affects both men and women; some studies suggest a slightly higher frequency in men [18][19]
Global Reach Cases have been reported worldwide across all ethnic backgrounds [17][20]

The “Diagnostic Odyssey”

Because the symptoms of ECD—such as bone pain, fatigue, or shortness of breath—can mimic many other conditions, the journey to a diagnosis is often long and exhausting [8]. This is frequently called a diagnostic odyssey.

It is not uncommon for patients to wait months or even several years to get the correct answer [2]. Some patients are initially misdiagnosed with conditions like Multiple Sclerosis (MS) or other inflammatory diseases because the imaging looks similar [21][22]. You may have had multiple biopsies that came back “inconclusive” before a specialist finally recognized the specific markers of ECD under the microscope [23].

The Emotional Reality

Living with a disease that is both “invisible” and ultra-rare carries a unique emotional burden. You may find yourself having to explain your condition to every nurse or new doctor you meet. Many patients report a high “symptom burden,” dealing with significant fatigue or “brain fog” that affects their quality of life [24].

Because the disease is so rare, you might feel isolated. However, understanding that ECD is now recognized as a specific neoplastic (cancerous) process has changed everything: it has allowed doctors to develop targeted tests and treatments that were not possible just a decade ago [11]. Identifying your specific genetic mutation is often the first step in moving from the “odyssey” of searching for answers to the active phase of managing the disease.

Common questions in this guide

What is Erdheim-Chester disease?
Erdheim-Chester disease is a rare disorder in which abnormal immune cells called histiocytes build up in tissues. It can affect several organs and cause both tissue changes and inflammation.
Is Erdheim-Chester disease caused by an inherited mutation?
Usually, mutations linked to Erdheim-Chester disease, such as BRAF V600E or other MAPK-pathway changes, are acquired in disease cells during a person’s life. They are generally not inherited or passed to children, although a negative mutation test does not rule out the disease.
What does a negative BRAF test mean for an ECD diagnosis?
A negative BRAF result means that this specific mutation was not detected by the test used. It does not completely rule out Erdheim-Chester disease because other mutations may drive the disease, and some patients have no identifiable mutation.
Why can Erdheim-Chester disease take a long time to diagnose?
The disease is exceptionally rare, and symptoms such as bone pain, fatigue, and shortness of breath can resemble more common illnesses. Imaging may look like other inflammatory conditions, and a biopsy may need review by a pathologist experienced in rare histiocytic diseases.
Which parts of the body can Erdheim-Chester disease affect?
Erdheim-Chester disease most often involves the long bones of the legs, but it can also affect the heart, lungs, brain, and tissues behind the kidneys. The organs involved vary from person to person, so imaging and specialist evaluation help identify the extent of disease.
How should I prepare for an Erdheim-Chester disease specialist visit?
Bring your biopsy and genetic-testing reports, imaging results, and a timeline of symptoms such as pain, fatigue, shortness of breath, or brain fog. Ask whether a specialist pathologist reviewed the biopsy, which mutations were tested, and which organs are involved.

Get notified when new evidence is published on Erdheim-Chester disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Perioperative multidisciplinary rescue of a patient with Erdheim - Chester disease and multi-system involvement: a case report.

    Wang Z, Yin S, Wang L, Liao B

    Frontiers in medicine 2026; (13()):1725570 doi:10.3389/fmed.2026.1725570.

    PMID: 41695166
  2. 2

    Solving a Mystery . . . 8 Years Later.

    Jouni H, Kuzo RS, Anavekar NS

    Journal of investigative medicine high impact case reports 2018; (6()):2324709617752962 doi:10.1177/2324709617752962.

    PMID: 29435464
  3. 3

    Imaging in Erdheim-Chester Disease.

    Aswani Y, Patel A, Zhan X, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2024; (44(9)):e240011 doi:10.1148/rg.240011.

    PMID: 39172709
  4. 4

    Non-langerhans cell histiocytosis: A growing category of emerging entities.

    Delio M, Duarte C, Siegele BJ, et al.

    Human pathology 2026; 106177 doi:10.1016/j.humpath.2026.106177.

    PMID: 42208771
  5. 5

    Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.

    Haroun F, Millado K, Tabbara I

    Anticancer research 2017; (37(6)):2777-2783 doi:10.21873/anticanres.11629.

    PMID: 28551613
  6. 6

    Erdheim-Chester disease.

    Starkebaum G, Hendrie P

    Best practice & research. Clinical rheumatology 2020; (34(4)):101510 doi:10.1016/j.berh.2020.101510.

    PMID: 32305313
  7. 7

    Histiocytic disorders.

    McClain KL, Bigenwald C, Collin M, et al.

    Nature reviews. Disease primers 2021; (7(1)):73 doi:10.1038/s41572-021-00307-9.

    PMID: 34620874
  8. 8

    The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease.

    Goyal G, Young JR, Koster MJ, et al.

    Mayo Clinic proceedings 2019; (94(10)):2054-2071 doi:10.1016/j.mayocp.2019.02.023.

    PMID: 31472931
  9. 9

    Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer.

    Cavalli G, Dagna L, Biavasco R, et al.

    Journal of leukocyte biology 2020; (108(2)):591-599 doi:10.1002/JLB.3MR0120-203RR.

    PMID: 32056262
  10. 10

    Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.

    Garg N, Lavi ES

    Journal of neuroimaging : official journal of the American Society of Neuroimaging 2021; (31(1)):35-44 doi:10.1111/jon.12785.

    PMID: 32920940
  11. 11

    Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.

    Goyal G, Heaney ML, Collin M, et al.

    Blood 2020; (135(22)):1929-1945 doi:10.1182/blood.2019003507.

    PMID: 32187362
  12. 12

    Cardiovascular manifestations of Erdheim-Chester disease.

    Ghotra AS, Thompson K, Lopez-Mattei J, et al.

    Echocardiography (Mount Kisco, N.Y.) 2019; (36(2)):229-236 doi:10.1111/echo.14231.

    PMID: 30569522
  13. 13

    Erdheim-Chester disease.

    Haroche J, Cohen-Aubart F, Amoura Z

    Blood 2020; (135(16)):1311-1318 doi:10.1182/blood.2019002766.

    PMID: 32107533
  14. 14

    The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

    Ozkaya N, Rosenblum MK, Durham BH, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(4)):581-597 doi:10.1038/modpathol.2017.160.

    PMID: 29192649
  15. 15

    Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.

    Allen CE, Parsons DW

    Hematology. American Society of Hematology. Education Program 2015; (2015()):559-64 doi:10.1182/asheducation-2015.1.559.

    PMID: 26637772
  16. 16

    Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.

    Yuen CA, Bao S, Aung MS, et al.

    Personalized medicine 2024; (21(2)):71-78 doi:10.2217/pme-2023-0137.

    PMID: 38275171
  17. 17

    Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.

    Toya T, Ogura M, Toyama K, et al.

    Haematologica 2018; (103(11)):1815-1824 doi:10.3324/haematol.2018.190728.

    PMID: 29976744
  18. 18

    Neuroradiologic manifestations of Erdheim-Chester disease.

    Parks NE, Goyal G, Go RS, et al.

    Neurology. Clinical practice 2018; (8(1)):15-20 doi:10.1212/CPJ.0000000000000422.

    PMID: 29517068
  19. 19

    Multisystem Radiologic Manifestations of Erdheim-Chester Disease.

    Lodhi U, Sarmast U, Khan S, Yaddanapudi K

    Case reports in radiology 2016; (2016()):2670495 doi:10.1155/2016/2670495.

    PMID: 27340583
  20. 20

    Erdheim-Chester disease presenting with multisystem involvement: A case report.

    Haq M, Bukhari SMRUAN, Basit A, et al.

    World journal of clinical cases 2026; (14(2)):115462 doi:10.12998/wjcc.v14.i2.115462.

    PMID: 41608151
  21. 21

    Erdheim-Chester disease: misdiagnosed as multiple sclerosis.

    Yang J, Imlay-Gillespie L, Dierkes JG, Khoo TK

    Practical neurology 2024; (24(2)):144-147 doi:10.1136/pn-2023-003865.

    PMID: 37932040
  22. 22

    Erdheim-Chester disease of brain parenchyma without any systemic involvement: A case report and review of literature.

    Aktan Suzgun M, Everest E, Kucukyurt S, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2024; (44(1)):59-67 doi:10.1111/neup.12930.

    PMID: 37357975
  23. 23

    [Difficult diagnosis of Erdheim Chester disease revealed by central diabetes insipidus].

    Alaya W, Zantour B, Ben Salem W, et al.

    Revue medicale de Liege 2017; (72(10)):436-438.

    PMID: 29058834
  24. 24

    Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease.

    Goyal G, Reiner AS, Bossert D, et al.

    Blood 2025; (145(18)):2100-2103 doi:10.1182/blood.2024028032.

    PMID: 40053897

This page is for informational purposes only and does not constitute medical advice about Erdheim-Chester disease. Discuss biopsy review, mutation testing, and organ involvement with a specialist familiar with ECD.

Guide contents Erdheim-Chester disease
Patient Resources Research & Literature
02 Symptoms, Complications & Warning Signs of ECD